Helus Pharma stock
HELPNASDAQHelus Pharma Inc., HealthcareISIN CA4234921076
40Score 40 out of 100, Weak
Price and trend
68 / 100
Price history
+50% since 2025The chart shows daily closing prices since 8 Dec 2025, adjusted for stock splits and excluding dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 14% above it.
Normal: the price is neither overheated nor sold off (RSI 39).
The price is 37% below its 52-week high. Largest decline since 8 Dec 2025: 56% (December 2025 to June 2026).
Chart figures for advanced users
- SMA 50$11.29
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$7.78
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)39
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$3.87
- The lowest closing price of the last twelve months.
- Resistance$14.02
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Helus Pharma Inc. belongs to the Biotechnology industry (Canada) and, with a market value of $549.18M, is number 233 of 296 companies in its industry on MEQIRI.
- MEQIRI Score 40 out of 100 (Weak): rank 553 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $157.78M, financial debt $0.Stability 69
Weaknesses
- Loss-makingLoss of $147.05M over the last 12 months.Fundamentals 17
- Volatile share priceVolatility 88% a year over the last 12 months.Stability 69
- Negative free cash flowFree cash flow −$133.79M over the last 12 months.Fundamentals 17
The score is held back by fundamentals and profitability.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 39 to 40.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredClosing price of 11 Nov 2026, used by the daily score.
No fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
Revenue ended the period negative (−$44.68M in the latest year). From 2025 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2026: gross 0%, operating 0%, net 0%. From 2025 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Debt & balance sheet
Fiscal 2026No financial debt is reported on the balance sheet.
Earnings
- Next earnings
- 12 Nov 2026today
- Last reported
- 14 Aug 2026EPS reported −$0.91 (expected −$0.80)below expectations
Analyst estimates
Analysts have raised their 2028 earnings estimate by 5.7% since 15 Oct 2026.
- Earnings per share
- −$2.67+0.3%
- Revenue
- $31.7M0.0%
- Earnings per share
- −$2.12+5.7%
- Revenue
- $10.13M+8.2%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Insiders
Open-market purchases and sales by executives, board members and major holders
One insider bought on the open market in the last 6 months, $38,730 in total.
- Cavers GregPurchase
29 Sept 2026, Chief Financial Officer
- Shares
- 3,000
- Price
- $12.91
- Value
- $38,730
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Helus Pharma
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 40
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- GeronGERN $657.12M35
- Capricor TherapeuticsCAPR $649.77M32
- Monopar TherapeuticsMNPR $612.75M42
- GenfitGNFT.PA $609.09M44
- Adlai NortyeANL $575.92M36
- ValnevaVLA.PA $567.35M31
- Entera BioENTX $560.72M44
- REGENXBIORGNX $560.06M32
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 31 Mar 2026
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 15 Oct 2026)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.